Zobrazeno 1 - 10
of 230
pro vyhledávání: '"Davide Tassinari"'
Autor:
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio, on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Methods Pts with prev
Externí odkaz:
https://doaj.org/article/8dc2e19ba5544857a0d837544b55b59a
Autor:
Maria Di Bartolomeo, Monica Niger, Federica Morano, Salvatore Corallo, Maria Antista, Stefano Tamberi, Sara Lonardi, Samantha Di Donato, Rossana Berardi, Mario Scartozzi, Giovanni Gerardo Cardellino, Francesco Di Costanzo, Lorenza Rimassa, Alberto Gianluigi Luporini, Raffaella Longarini, Alberto Zaniboni, Alessandro Bertolini, Gianluca Tomasello, Graziella Pinotti, Giorgio Scagliotti, Giampaolo Tortora, Andrea Bonetti, Andrea Spallanzani, Giovanni Luca Frassineti, Davide Tassinari, Francesco Giuliani, Saverio Cinieri, Evaristo Maiello, Claudio Verusio, Sergio Bracarda, Vincenzo Catalano, Michele Basso, Libero Ciuffreda, Ferdinando De Vita, Hector Soto Parra, Lorenzo Fornaro, Marta Caporale, Filippo de Braud, Filippo Pietrantonio
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4–6 cy
Externí odkaz:
https://doaj.org/article/d0e8c64069684a23a1a693ea53c572e0
Autor:
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Alessio Cortellini, Francesco Verderame, Vincenzo Montesarchio, Mimma Rizzo, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Saverio Cinieri, Giorgia Negrini, Maria Banzi, Mariella Sorarù, Paolo Andrea Zucali, Gaetano Lacidogna, Antonio Russo, Nicola Battelli, Giuseppe Fornarini, Claudia Mucciarini, Sergio Bracarda, Andrea Bonetti, Debora Pezzuolo, Lucia Longo, Donata Sartori, Mauro Iannopollo, Luigi Cavanna, Fausto Meriggi, Davide Tassinari, Claudia Corbo, Angela Gernone, Veronica Prati, Simona Carnio, Pasqualina Giordano, Angela Maria Dicorato, Claudio Verusio, Francesco Atzori, Francesco Carrozza, Stefania Gori, Antonino Castro, Sara Pilotto, Vanja Vaccaro, Elisabetta Garzoli, Francesco Di Costanzo, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Michele Tognetto, Sebastiano Buti
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from O
Externí odkaz:
https://doaj.org/article/56f65524e4484c51b38e78016965cac1
Autor:
Elisabetta Petracci, Emanuela Scarpi, Alessandro Passardi, Annibale Biggeri, Carlo Milandri, Stefano Vecchia, Fabio Gelsomino, Davide Tassinari, Stefano Tamberi, Ilaria Bernardini, Caterina Accettura, Giovanni Luca Frassineti, Dino Amadori, Oriana Nanni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Cancer trials involving multiple treatment lines substantially increase our understanding of therapeutic strategies. However, even when the primary end-point of these studies is progression-free survival (PFS), their statistical analysis
Externí odkaz:
https://doaj.org/article/f2076c860f5b400f8b894c34d14186f5
Autor:
Alessandro Passardi, Emanuela Scarpi, Stefano Tamberi, Luigi Cavanna, Davide Tassinari, Annalisa Fontana, Sara Pini, Ilaria Bernardini, Caterina Accettura, Paola Ulivi, Giovanni Luca Frassineti, Dino Amadori
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134732 (2015)
To investigate the impact of pre-treatment lactate dehydrogenase (LDH) levels on the outcome of patients with metastatic colorectal cancer treated with first-line chemotherapy with or without the anti-VEGF monoclonal antibody, bevacizumab, in a phase
Externí odkaz:
https://doaj.org/article/3643ecd5c34140ea96d66c3eb87872f7
Autor:
Giorgia Gurioli, Gianluca Tedaldi, Alberto Farolfi, Elisabetta Petracci, Claudia Casanova, Giuseppe Comerci, Rita Danesi, Valentina Arcangeli, Mila Ravegnani, Daniele Calistri, Valentina Zampiga, Ilaria Cangini, Eugenio Fonzi, Alessandra Virga, Davide Tassinari, Marta Rosati, Paola Ulivi, Ugo De Giorgi
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 24; Pages: 15789
BRCA1 and BRCA2 are the most frequently mutated genes in ovarian cancer (OC) crucial both for the identification of cancer predisposition and therapeutic choices. However, germline variants in other genes could be involved in OC susceptibility. We ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d123df75176f2238b88c86e4276141
Autor:
Matteo Donadon, Angela Palmisano, Mariano Bizzarri, Roberto Ceriani, Luigi Veneroni, Gabriele Donati, Davide Tassinari, Massimo Giuseppe Viola, Emiliano Tamburini, Guido Torzilli
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2809
Background: Previous studies on oocyte extract supplementation showed benefits in patients with liver tumours. In this trial, we hypothesized that the oocyte extract supplement impacted the QoL after hepatectomy for hepatocellular carcinoma and intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2019d01a934b12d16652427a02770c3a
https://doi.org/10.3390/cancers15102809
https://doi.org/10.3390/cancers15102809
Autor:
Emiliano Tamburini, Davide Tassinari, Matteo Ramundo, Alfonso De Stefano, Massimo Giuseppe Viola, Carmela Romano, Maria Teresa Elia, Nicoletta Zanaletti, Britt Rudnas, Andrea Casadei-Gardini, Paolo Delrio, Ilaria Toma, Vincenza Granata, Luciana Petrucelli, Antonio Avallone
Publikováno v:
Critical reviews in oncology/hematology. 172
Although no definitive data exist in literature, adjuvant chemotherapy is usually recommended in patients with radically resected stage III rectal cancer treated with neo-adjuvant chemo-radiotherapy. We performed a systematic review of literature wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eacdfb19a7e405b61e6318edb8a5a21
https://pubmed.ncbi.nlm.nih.gov/35202817
https://pubmed.ncbi.nlm.nih.gov/35202817
Autor:
Stefano Tamberi, Elisa Grassi, Chiara Zingaretti, Giorgio Papiani, Sara Pini, Jody Corbelli, Maria Di Bartolomeo, Filippo Pietrantonio, Giovanni Luca Frassineti, Alessandro Passardi, Fabio Gelsomino, Marina Marzola, Maria Banzi, Andrea Vincent Bonetti, Elisabetta Petracci, Chiara Carli Moretti, Isabella Banchelli, Davide Tassinari, Giampaolo Ugolini, Oriana Nanni
Publikováno v:
Journal of Clinical Oncology. 40:LBA3513-LBA3513
LBA3513 Background: The combination of capecitabine plus long course radiotherapy (RT) is the standard preoperative therapy in cT3-4 cN+ rectal cancer. pathologic complete remission (pCR) can be considered as surrogate endpoint of efficacy of treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9639352329a7d8e1716527e54e76e4f1
https://doi.org/10.1200/jco.2022.40.17_suppl.lba3513
https://doi.org/10.1200/jco.2022.40.17_suppl.lba3513
Autor:
Davide Tassinari
Il tema dei profili sostanziali del nemo tenetur se detegere è stato di rado analizzato dalla letteratura penalistica italiana, che se ne è occupata in pochi – ma assai pregevoli – studi. La possibile valenza del principio quale causa di non pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c37271ae3bc6a4277c0de561cb602bc
https://doi.org/10.30682/sg263
https://doi.org/10.30682/sg263
